Arrowhead Pharmaceuticals (NasdaqGS:ARWR) Q1 2026 Earnings call February 05, 2026 04:30 PM ET Company ParticipantsAndrea Newkirk - SVP of Biotechnology Equity ResearchAndy Davis - SVP and Head of Global Cardiometabolic FranchiseChris Anzalone - President and CEODan Apel - CFOEdward Tenthoff - Managing DirectorJames Hamilton - Chief Medical Officer and Head of R&DJason Gerberry - Managing DirectorJoseph Thome - Managing DirectorMani Foroohar - Managing DirectorMike Ulz - Executive DirectorPatrick Trucchio - ...

Privium Fund Management reported a sale of 75,747 shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) in a February 2 SEC filing, with the estimated trade value at $3.71 million based on quarterly average pricing. What happened According to a SEC filing dated February 2, Privium Fund Management reduced its position in Arrowhead Pharmaceuticals by 75,747 shares in the fourth quarter. The estimated value of this share sale was $3.71 million, based on the mean unadjusted closing price during the quarter. Mean ...

Company Overview - Arrowhead Pharmaceuticals is identified by the ticker symbol ARWR, with a stock price of $64.56 as of the last trading day [3] - The company has approximately 136 million shares outstanding, resulting in a market capitalization of around $9 billion [3] - As of the latest filing, Arrowhead has about $920 million in cash and investments, excluding $200 million from Sarepta that has been invoiced but not yet received, and $200 million from Novartis that has been received but not yet reflected in filings [3] Business Focus - The primary objective of Arrowhead Pharmaceuticals is to bring RNA interference technology to patients [4] - The company has achieved its first commercial launch with the product REDEMPLO, which has been approved in both the U.S. and Canada [4]

Arrowhead Pharmaceuticals Conference Call Summary Company Overview - **Company**: Arrowhead Pharmaceuticals (NasdaqGS:ARWR) - **Focus**: Development of obesity therapeutics, specifically targeting the activin E ALK7 pathway and its implications for metabolic diseases Key Points from the Call Industry and Market Context - **Obesity Treatment Landscape**: The call highlighted the evolving understanding of obesity as a multifaceted disease requiring diverse treatment approaches, including pharmacotherapy, surgical options, and lifestyle changes [2][4][5] - **Unmet Needs**: There is a significant unmet need in treating obesity, particularly in patients with Type 2 diabetes, who often do not respond well to existing therapies [5][14][24] Clinical Trials and Results - **ARO-INHBE and ARO-ALK7**: The call presented interim results from Phase I and II studies of two obesity candidates, ARO-INHBE and ARO-ALK7, focusing on their efficacy and safety [2][3][30] - **Interim Results**: - ARO-INHBE demonstrated a mean maximal reduction of activin E by 85% at a 400 mg dose, leading to a 10% reduction in visceral fat and a 38% reduction in liver fat after a single dose [20][34] - In combination with tirzepatide, ARO-INHBE achieved a 9.4% weight loss in obese diabetic patients, compared to 4.8% with tirzepatide alone [25][35] - ARO-ALK7 showed an 88% mean reduction in ALK7 mRNA after a single dose, with a 14.1% placebo-adjusted reduction in visceral fat observed at week eight [32][36] Mechanism of Action - **Activin E ALK7 Pathway**: The pathway is implicated in regulating visceral adiposity, and silencing its expression may lead to improved metabolic outcomes [17][18][27] - **Combination Therapy**: The combination of ARO-INHBE with tirzepatide is seen as a promising approach to enhance weight loss and metabolic health in patients with obesity and Type 2 diabetes [24][35] Safety and Tolerability - **Safety Profile**: ARO-INHBE and ARO-ALK7 were reported to be well tolerated, with most treatment-emergent adverse events (TEAEs) being mild and no significant adverse trends in laboratory values [27][33] Future Directions - **Next Steps**: Arrowhead plans to expand its studies, including increasing patient numbers and exploring combination therapies with other GLP-1 drugs [38][39] - **Regulatory Pathway**: Discussions regarding the regulatory pathway for ARO-INHBE and ARO-ALK7 are ongoing, with a focus on combination therapies for diabetic patients [51][52] Additional Insights - **Research and Development**: Arrowhead is exploring additional targets in obesity and metabolic disorders, including liver and adipose dimers capable of silencing multiple genes with a single drug [39][40] - **Commercialization Plans**: The company is transitioning to a commercial stage with its first sales expected in the FCS patient population, with further studies planned to support label expansion [40][41] Conclusion Arrowhead Pharmaceuticals is making significant strides in the development of innovative obesity therapeutics, with promising interim results from its clinical trials. The focus on the activin E ALK7 pathway and combination therapies positions the company well in addressing the unmet needs in obesity treatment, particularly for patients with Type 2 diabetes. The safety and efficacy data presented suggest a strong potential for these candidates in future therapeutic paradigms.

Core Viewpoint - Arrowhead Pharmaceuticals has received FDA approval for REDEMPLO, a treatment aimed at reducing triglycerides in adults with familial chylomicronemia syndrome (FCS) [2]. Group 1: FDA Approval - The FDA approval of REDEMPLO is a significant milestone for Arrowhead Pharmaceuticals, as it addresses a critical need for patients suffering from FCS [2]. Group 2: Financial and Investor Relations - Vince Anzalone, Vice President of Finance and Investor Relations, is leading the discussion on the implications of this approval for the company's future [1].

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]